D. Scott Wilbur

4.9k total citations
150 papers, 3.7k citations indexed

About

D. Scott Wilbur is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, D. Scott Wilbur has authored 150 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Radiology, Nuclear Medicine and Imaging, 29 papers in Pulmonary and Respiratory Medicine and 26 papers in Oncology. Recurrent topics in D. Scott Wilbur's work include Radiopharmaceutical Chemistry and Applications (108 papers), Monoclonal and Polyclonal Antibodies Research (43 papers) and Medical Imaging Techniques and Applications (33 papers). D. Scott Wilbur is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (108 papers), Monoclonal and Polyclonal Antibodies Research (43 papers) and Medical Imaging Techniques and Applications (33 papers). D. Scott Wilbur collaborates with scholars based in United States, Canada and South Africa. D. Scott Wilbur's co-authors include Donald K. Hamlin, Michael J. Adam, Ming‐Kuan Chyan, Oliver W. Press, John M. Pagel, Robert L. Vessella, Brenda M. Sandmaier, Mark D. Hylarides, Pradip M. Pathare and Darrell R. Fisher and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Chemical Society Reviews and Blood.

In The Last Decade

D. Scott Wilbur

145 papers receiving 3.6k citations

Peers

Countries citing papers authored by D. Scott Wilbur

Since Specialization

Citations

This map shows the geographic impact of D. Scott Wilbur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scott Wilbur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scott Wilbur more than expected).

Fields of papers citing papers by D. Scott Wilbur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Scott Wilbur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scott Wilbur. The network helps show where D. Scott Wilbur may publish in the future.

Co-authorship network of co-authors of D. Scott Wilbur

This figure shows the co-authorship network connecting the top 25 collaborators of D. Scott Wilbur. A scholar is included among the top collaborators of D. Scott Wilbur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Scott Wilbur. D. Scott Wilbur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Production and purification of research scale ¹⁶¹Tb using cation-exchange semi-preparative HPLC for radiopharmaceutical applications 2025 ·Radiochimica Acta ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dmitri Medvedev, Cathy S. Cutler, D. Scott Wilbur, Yawen Li, Carolyn J. Anderson, Silvia S. Jurisson, Heather M. Hennkens	0
2	CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model 2024 ·Blood ·Stefan Radtke, (unknown), George S. Laszlo, (unknown), (unknown), Nicholas Petty, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier, Hans‐Peter Kiem, Roland B. Walter	0
3	Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors 2023 ·Clinical Cancer Research ·Johnnie J. Orozco, (unknown), Ted Gooley, (unknown), (unknown), (unknown), D. Scott Wilbur, Manuela C. Matesan, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, John M. Pagel, Brenda M. Sandmaier	2
4	[ ²¹¹ At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies 2023 ·Leukemia & lymphoma ·George S. Laszlo, Brenda M. Sandmaier, (unknown), Johnnie J. Orozco, Donald K. Hamlin, (unknown), (unknown), (unknown), (unknown), D. Scott Wilbur, Roland B. Walter	2
5	Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies 2022 ·Leukemia ·George S. Laszlo, Johnnie J. Orozco, (unknown), (unknown), (unknown), Donald K. Hamlin, D. Scott Wilbur, (unknown), Melissa L. Comstock, Shyril O’Steen, Brenda M. Sandmaier, Damian J. Green, Roland B. Walter	15
6	Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review 2021 ·Journal of Nuclear Medicine ·Hua Yang, Justin J. Wilson, Chris Orvig, Yawen Li, D. Scott Wilbur, Caterina F. Ramogida, Valery Radchenko, Paul Schaffer	58
7	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA 2020 ·Molecular Cancer Therapeutics ·Johnnie J. Orozco, Aimee L. Kenoyer, Yukang Lin, Shyril O’Steen, (unknown), (unknown), (unknown), Mark D. Hylarides, Darrell R. Fisher, (unknown), Donald K. Hamlin, D. Scott Wilbur, Kelly Davis Orcutt, K. Dane Wittrup, Damian J. Green, Ajay K. Gopal, Brian G. Till, Brenda M. Sandmaier, Oliver W. Press, John M. Pagel	8
8	A Solid-State Support for Separating Astatine-211 from Bismuth 2020 ·Inorganic Chemistry ·David H. Woen, (unknown), (unknown), Nickolas H. Anderson, (unknown), Eva R. Birnbaum, Anastasia V. Blake, (unknown), (unknown), (unknown), Maryline G. Ferrier, Donald K. Hamlin, Stosh A. Kozimor, Yawen Li, Laura M. Lilley, Veronika Mocko, (unknown), D. Scott Wilbur, Frankie D. White	16
9	Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. 2020 ·Nuclear Medicine and Biology ·Yawen Li, Ming‐Kuan Chyan, Donald K. Hamlin, Holly M. Nguyen, Robert L. Vessella, D. Scott Wilbur	10
10	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas 2017 ·Cancer Research ·Shyril O’Steen, Damian J. Green, Ajay K. Gopal, Johnnie J. Orozco, Aimee L. Kenoyer, Yukang Lin, D. Scott Wilbur, Donald K. Hamlin, Darrell R. Fisher, Mark D. Hylarides, Theodore A. Gooley, (unknown), Brian G. Till, Oliver W. Press	23
11	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers 2016 ·Cancer Research ·Damian J. Green, Shani L. Frayo, Yukang Lin, Donald K. Hamlin, Darrell R. Fisher, Sofia H.L. Frost, Aimee L. Kenoyer, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Shyril O’Steen, Kelly Davis Orcutt, D. Scott Wilbur, K. Dane Wittrup, Oliver W. Press	22
12	²¹¹ Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy 2015 ·Human Gene Therapy ·Christopher R. Burtner, (unknown), Erlinda B. Santos, Brian C. Beard, Jennifer E. Adair, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier, Hans‐Peter Kiem	13
13	In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model 2014 ·Cancer Research ·(unknown), Aimee L. Kenoyer, Johnnie J. Orozco, (unknown), Mazyar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hylarides, Oliver W. Press, D. Scott Wilbur, John M. Pagel	19
14	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies 2013 ·Cancer Research ·Damian J. Green, Nural Orgun, Jon C. Jones, Mark D. Hylarides, John M. Pagel, Donald K. Hamlin, D. Scott Wilbur, Yukang Lin, Darrell R. Fisher, Aimee L. Kenoyer, Shani L. Frayo, Ajay K. Gopal, Johnnie J. Orozco, Theodore A. Gooley, Brent L. Wood, William Bensinger, Oliver W. Press	40
15	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model 2013 ·Blood ·Johnnie J. Orozco, Tom Bäck, Aimee L. Kenoyer, (unknown), Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Shani L. Frayo, Mark D. Hylarides, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel	54
16	Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma 2011 ·Clinical Cancer Research ·Steven Park, (unknown), (unknown), Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark D. Hylarides, Franz Buchegger, Aimee L. Kenoyer, (unknown), Ajay K. Gopal, Damian J. Green, John M. Pagel, Oliver W. Press	27
17	Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides 2011 ·Current Radiopharmaceuticals ·D. Scott Wilbur	41
18	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211 2009 ·Cancer Research ·Hirohisa Nakamae, D. Scott Wilbur, Donald K. Hamlin, Monica S. Thakar, Erlinda B. Santos, Darrell R. Fisher, Aimee L. Kenoyer, John M. Pagel, Oliver W. Press, Rainer Storb, Brenda M. Sandmaier	43
19	Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Eneida R. Nemecek, Damian J. Green, Darrell R. Fisher, John M. Pagel, Yukang Lin, Ajay K. Gopal, Lawrence D. Durack, Joseph G. Rajendran, D. Scott Wilbur, Rune Nilsson, Bengt Sandberg, Oliver W. Press	5
20	Preparation and evaluation of N-acylated anthracycline analogues for radiolabelling with I-124 and Br-76 - potential radiotracers for in vivo assessment of multidrug resistance 1998 ·Journal of Labelled Compounds and Radiopharmaceuticals ·Jane Sosabowski, Jamal Zweit, Helen M. Coley, (unknown), D. Scott Wilbur, Donald K. Hamlin, P. Carnochan, I. Judson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact